These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
16. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease. Tullos NA; Stewart NJ; Davidovich R; Chade AR Nephrol Dial Transplant; 2015 Apr; 30(4):584-93. PubMed ID: 25438341 [TBL] [Abstract][Full Text] [Related]
17. Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH). Sarafidis PA; Theodorakopoulou M; Ortiz A; Fernandez-Fernández B; Nistor I; Schmieder R; Arici M; Saratzis A; Van der Niepen P; Halimi JM; Kreutz R; Januszewicz A; Persu A; Cozzolino M Nephrol Dial Transplant; 2023 Nov; 38(12):2835-2850. PubMed ID: 37202218 [TBL] [Abstract][Full Text] [Related]
18. Antioxidant intervention blunts renal injury in experimental renovascular disease. Chade AR; Rodriguez-Porcel M; Herrmann J; Zhu X; Grande JP; Napoli C; Lerman A; Lerman LO J Am Soc Nephrol; 2004 Apr; 15(4):958-66. PubMed ID: 15034098 [TBL] [Abstract][Full Text] [Related]
19. Percutaneous revascularization for ischemic nephropathy: the past, present, and future. Textor SC; Misra S; Oderich GS Kidney Int; 2013 Jan; 83(1):28-40. PubMed ID: 23151953 [TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and management of renovascular hypertension and ischemic nephropathy. Yerram P; Karuparthi PR; Chaudhary K Minerva Urol Nefrol; 2012 Mar; 64(1):63-72. PubMed ID: 22402318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]